Monoclonal Antibodies
Octreotide + Interferon/Bevacizumab for Neuroendocrine Tumors
Recruiting2 awardsPhase 3
Fort Smith, Arkansas
This trial is comparing two treatments for neuroendocrine tumors - octreotide acetate with either recombinant interferon alfa-2b or bevacizumab. The goal is to see if octreotide acetate with recombinant interferon alfa-2b is more effective than with bevacizumab.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Hot Springs, Arkansas
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Alkylating agents
Combination Chemotherapy + Stem Cell Transplant/Radiation for Retinoblastoma
Recruiting2 awardsPhase 3
Little Rock, Arkansas
This trial is studying side effects and how well giving a combination of chemotherapy and either an autologous stem cell transplant or radiation therapy works in treating young patients with extraocular retinoblastoma.
Popular Filters
Phase 3 Trials
Alkylating agents
Chemotherapy + Stem Cell Transplant for Brain Cancer
Recruiting2 awardsPhase 3
Little Rock, Arkansas
This trial is studying two different chemotherapy combinations to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma.
Trials With No Placebo
Alkylating agents
Chemotherapy + Stem Cell Transplant for Brain Cancer
Recruiting2 awardsPhase 3
Little Rock, Arkansas
This trial is studying two different chemotherapy combinations to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma.
Monoclonal Antibodies
Chemotherapy + Radiation + Bevacizumab for Lung Cancer
Recruiting1 awardPhase 2
Shreveport, Louisiana
This trial is testing a combination of chemotherapy drugs, radiation therapy, and the drug bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer.
Alkylating agents
Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma
Recruiting2 awardsPhase 2
Little Rock, Arkansas
This trial is studying how well surgery, radiation therapy, and/or combination chemotherapy work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.